{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:16:51Z","timestamp":1787984211206,"version":"build-2784847793"},"reference-count":14,"publisher":"Japan Neurosurgical Society","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.2176\/jns-nmc.2026-0128","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:14:17Z","timestamp":1787609657000},"page":"439-444","source":"Crossref","is-referenced-by-count":0,"title":["Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy"],"prefix":"10.2176","volume":"13","author":[{"given":"Ryuichi","family":"NODA","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, NTT Medical Center Tokyo"},{"name":"Gamma Knife Center, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"AKABANE","sequence":"additional","affiliation":[{"name":"Gamma Knife Center, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"KAWASHIMA","sequence":"additional","affiliation":[{"name":"Gamma Knife Center, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"SEGAWA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"SHIMOI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"MASUDA","sequence":"additional","affiliation":[{"name":"Department of Histopathology, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"MORIKAWA","sequence":"additional","affiliation":[{"name":"Department of Histopathology, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"USUI","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"INOUE","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NTT Medical Center Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Singh K, Saxena S, Khosla AA, et al. Update on the management of brain metastasis. Neurotherapeutics. 2022;19 (6):1772-81. doi: 10.1007\/s13311-022-01312-w","DOI":"10.1007\/s13311-022-01312-w"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Pellerino A, Bruno F, Rud\u00e0 R, et al. Systemic therapy for lung cancer brain metastases. Curr Treat Options Oncol. 2021;22 (12):110. doi: 10.1007\/s11864-021-00911-7","DOI":"10.1007\/s11864-021-00911-7"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21 (5):655-63. doi: 10.1016\/S1470-2045(20)30111-X","DOI":"10.1016\/S1470-2045(20)30111-X"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3 (75):75ra26. doi: 10.1126\/scitranslmed.3002003","DOI":"10.1126\/scitranslmed.3002003"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393 (10183):1819-30. doi: 10.1016\/S0140-6736(18)32409-7","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520 (7547):373-7. doi: 10.1038\/nature14292","DOI":"10.1038\/nature14292"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Hsieh MS, Lin MW, Lee YH. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. Lung Cancer. 2019;137:76-84. doi: 10.1016\/j.lungcan.2019.08.029","DOI":"10.1016\/j.lungcan.2019.08.029"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36 (28):2872-8. doi: 10.1200\/JCO.2018.79.0006","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Cohen JV, Alomari AK, Vortmeyer AO, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4 (3):179-82. doi: 10.1158\/2326-6066.CIR-15-0160","DOI":"10.1158\/2326-6066.CIR-15-0160"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clin Cancer Res. 2023;29 (14):2580-7. doi: 10.1158\/1078-0432.CCR-22-3181","DOI":"10.1158\/1078-0432.CCR-22-3181"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33 (18):2004-12. doi: 10.1200\/JCO.2014.58.3708","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Pala L, Pagan E, Sala I, et al. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis. EClinicalMedicine. 2024;73:102681. doi: 10.1016\/j.eclinm.2024.102681","DOI":"10.1016\/j.eclinm.2024.102681"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Frost N, Kollmeier J, Misch D, et al. Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (\u226550%) NSCLC: real-world results with special focus on PS \u22652, brain metastases, and steroids. Clin Lung Cancer. 2021;22 (5):411-22. doi: 10.1016\/j.cllc.2021.02.001","DOI":"10.1016\/j.cllc.2021.02.001"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Sehgal K, Gill RR, Widick P, et al. Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open. 2021;4 (2):e2037120. doi: 10.1001\/jamanetworkopen.2020.37120","DOI":"10.1001\/jamanetworkopen.2020.37120"}],"container-title":["NMC Case Report Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/13\/0\/13_2026-0128\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:29:50Z","timestamp":1787981390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/13\/0\/13_2026-0128\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12,31]]},"references-count":14,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2026-0128","relation":{},"ISSN":["2188-4226"],"issn-type":[{"value":"2188-4226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,12,31]]},"article-number":"2026-0128"}}